Anticonvulsant drug level monitoring often inappropriate

1995 ◽  
Vol &NA; (1014) ◽  
pp. 11
Author(s):  
&NA;
Keyword(s):  
Anticonvulsant Drug ◽  
Drug Level ◽  
Drug Level Monitoring ◽  
Level Monitoring

The necessity of drug level monitoring in anticonvulsant drug therapy

1976 ◽  
Vol 54 (6) ◽  
pp. 850-858 ◽  
Author(s):  
H. Lorne Davis ◽  
David G. Bailey ◽  
Gordon E. Johnson ◽  
Thomas W. Wilson
Keyword(s):  
Therapeutic Range ◽  
Anticonvulsant Drug ◽  
Drug Level ◽  
Serum Levels ◽  
Anticonvulsant Drugs ◽  
University Hospital ◽  
Steady State Serum ◽  
Gas Chromatographic Method ◽  
Drug Level Monitoring ◽  
Level Monitoring

A survey of 'steady-state' serum levels of anticonvulsant drugs from 221 epileptic patients at a university hospital was conducted. Serum concentrations of phenobarbital, primidone, and diphenylhydantoin were determined by a gas chromatographic method. Sixty-five percent (130) of the patients receiving diphenylhydantoin had levels below the therapeutic range of 10–20 μg/ml. Subtherapeutic levels appear to be due to inadequate dosage adjustment. Only 25% (33) of the patients receiving phenobarbital had levels below the therapeutic range. Serum levels of diphenylhydantoin or phenobarbital could not be predicted from dosage. Most patients received two or more drugs. Over 10% of the patients had potentially toxic levels of anticonvulsant drugs. High levels of diphenylhydantoin were easily recognized clinically but high levels of phenobarbital were not.

scholarly journals Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring

2019 ◽  
Vol 70 (3) ◽  
pp. 552-554 ◽  
Author(s):  
Minou van Seyen ◽  
Elise J. Smolders ◽  
Peter van Wijngaarden ◽  
Joost P.H. Drenth ◽  
Marjan Wouthuyzen-Bakker ◽  
...  
Keyword(s):  
Drug Level ◽  
Hcv Treatment ◽  
Drug Level Monitoring ◽  
Level Monitoring

Drug level monitoring in palliative patients

2021 ◽  
pp. bmjspcare-2020-002613
Author(s):  
Joanne Bartlett ◽  
Elizabeth Freshwater
Keyword(s):  
Brain Tumour ◽  
Palliative Medicine ◽  
Drug Level ◽  
Therapeutic Drug ◽  
Primary Brain Tumour ◽  
Drug Level Monitoring ◽  
Symptoms And Signs ◽  
Level Monitoring ◽  
Palliative Patients

Palliative medicine is always patient centred and promotes the principle that no unnecessary investigations are performed. The case is reported of a patient with suspected carbamazepine toxicity presenting as progression of symptoms of primary brain tumour. A comparison is made of the symptoms and signs of toxicity versus tumour, and an aid for deciding when to perform therapeutic drug level monitoring for some common drugs.

Methotrexate Blood Level Monitoring

1985 ◽  
Vol 19 (5) ◽  
pp. 372-373 ◽  
Author(s):  
Helen St.C. Remington ◽  
Clifford C. Bailey
Keyword(s):  
Blood Level ◽  
Fluid Balance ◽  
Drug Level ◽  
Therapeutic Drug ◽  
High Dose ◽  
High Dose Therapy ◽  
Methotrexate Toxicity ◽  
Management Procedures ◽  
Drug Level Monitoring ◽  
Level Monitoring

Methotrexate toxicity can be avoided following high-dose therapy if certain management procedures are adhered to. These include careful fluid balance management and therapeutic drug level monitoring. A case is reported of an episode of methotrexate toxicity resulting from a fluid balance problem.

scholarly journals Prescribing Habits for Theophylline Preparations

1983 ◽  
Vol 76 (11) ◽  
pp. 917-919 ◽  
Author(s):  
J K Wiffen ◽  
S H D Jackson
Keyword(s):  
Slow Release ◽  
Drug Level ◽  
Prescribing Habits ◽  
Serum Drug Level ◽  
Drug Level Monitoring ◽  
Level Monitoring

Information concerning the prescriptions for theophylline preparations for a group of 80 inpatients and 55 outpatients were examined. Slow-release preparations were overwhelmingly preferred. The majority of patients were receiving low daily doses of theophylline or equivalent, and serum drug level monitoring was almost non-existent.

Sign in / Sign up

Export Citation Format

Share Document